Skip to content
Screener

CareDx CDNA Q2 2026 earnings

Reported July 30, 2026 · After market close

Revenue$131.9MBeat by $17.9M
EPS$0.37Beat by $0.14
Revenue estimate$114.1M
EPS estimate$0.23
“Our performance reflects that our strategy is working, and we look forward to building on our momentum as we integrate NavDx and launch into cell therapy.”
John Hanna

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full
Revenue$131.9M+52.2%
Operating income$113.2M+1,118%
Net income$110.6M+1,391%
EPS (diluted)$2.07+1,394%

Balance sheet

See full
Cash & equivalents$373.6M+443%
Total debt$19.2M-33.9%
Total equity$425.6M+30.0%
Total assets$533.0M+20.0%

Cash flow

See full
Operating cash flow$30.6M+209%
CapEx$1.9M—
Free cash flow$28.7M—

Valuation & ratios

Valuation

as of 06/30/26
See full
Market cap$1.47B+40.1%
Enterprise value$1.12B+10.5%
P/E13.3×-4.8×
P/S3.2×+0.1×

Profitability

See full
Operating margin23.6%+10.1pp
Net margin24.2%+7.2pp

Returns & leverage

See full
Return on equity29.5%+9.8pp
Debt / equity0×0.0×
Current ratio4.6×+1.3×

Segments

By product

See full
Testing services revenue$99.9M+61.1%
Patient and digital solutions revenue$19.2M+50.1%

By segment

See full
Reportable Segment$131.9M+52.2%

FAQ

When did CareDx report Q2 2026 earnings?
CareDx (CDNA) reported Q2 2026 earnings on July 30, 2026 after market close.
What were CareDx's Q2 2026 revenue and EPS?
CareDx reported revenue of $131.9M and eps of $0.37 for Q2 2026.
Did CareDx beat estimates in Q2 2026?
Revenue beat the consensus estimate of $114.1M by $17.9M. EPS beat the consensus estimate of $0.23 by $0.14.
How did CareDx's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 52.2% from $86.7M a year earlier and eps grew 270.0% from $0.10.
Where can I find CareDx's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001217234-26-000045) and the 10-Q periodic report (0001217234-26-000046) directly on SEC EDGAR. The filing index links above go to sec.gov.